Trump Revokes Biden's Order to Lower Drug Prices for Medicare
Biden's Executive Order to lower copays for some drugs to $2 for Medicare and Medicaid enrollees is nixed by President Trump.


President Donald Trump has been busy rescinding Biden-era Executive Orders in his first days in office, including one that had the potential to lower the cost of prescription drugs for Americans on Medicare.
Known as Executive Order 14087, it was designed to identify a list of prescription drugs that would, under the plan, require only a $2 copay a month for anyone on Medicare. Former President Biden had directed the Center for Medicare and Medicaid Innovation, an arm of the Centers for Medicare and Medicaid Services, to look into ways to make prescription drugs cheaper for Medicare recipients.
“Too many Americans face challenges paying for prescription drugs. On average, Americans pay two to three times as much as people in other countries for prescription drugs, and one in four Americans who take prescription drugs struggle to afford their medications,” Biden said at the time. “Nearly 3 in 10 American adults who take prescription drugs say that they have skipped doses, cut pills in half, or not filled prescriptions due to cost.”

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Lowering drugs costs for Medicare enrollees
Drugs that were identified to be included on the Medicare $2 Drug List Model included ones to treat diabetes, high cholesterol and thyroid issues. The model aimed to “standardize cost sharing for low-cost generics through a new, easy-to-understand option for people with Medicare Part D enrolled in a participating plan and their health care providers,” wrote CMS when originally announcing the plan.
Other parts of the executive order included improving access to cell and gene therapies, which have high costs associated with them, and accelerating the evidence-gathering process for new drugs. Trump’s new executive order would take those mandates away from CMS.
More Medicare changes in the works?
In rescinding Biden’s executive order on prescription drugs and many others, Trump said, “The previous administration has embedded deeply unpopular, inflationary, illegal, and radical practices within every agency and office of the Federal Government.” He warned, “The revocations within this order will be the first of many steps the United States Federal Government will take to repair our institutions and our economy.” Other Medicare and Medicaid existing laws and regulations around prescription drugs remain in effect for now.
It's unclear what Trump will do about Medicare's ability to negotiate lower drug prices under the Inflation Reduction Act, put on the books in 2022. The Act allows Medicare to negotiate drug prices directly with pharmaceutical companies for the first time. President Trump hasn’t said if he supports the government’s ability to negotiate with the drug companies directly.
In the first round, Medicare negotiated lower prices for ten drugs. Last week, Medicare announced that it planned to negotiate prices for another 15 medications, including the popular weight-loss drugs Ozempic and Wegovy. The high costs associated with these drugs, which have proven effective, have been fiercely criticized by consumers.
Related content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Donna Fuscaldo is the retirement writer at Kiplinger.com. A writer and editor focused on retirement savings, planning, travel and lifestyle, Donna brings over two decades of experience working with publications including AARP, The Wall Street Journal, Forbes, Investopedia and HerMoney.
-
Ten Cheapest Places To Live in Florida
Property Tax Make your Florida vacation spot daily living — these counties have the lowest property tax bills in the state.
By Kate Schubel
-
I'm 50 and my home is worth $5 million. Can I retire now?
It may be oh-so tempting to cash out your upscale home and leave work for good. But should you? We ask the experts.
By Maurie Backman
-
I'm 50 and My Home Is Worth $5 Million. Can I Retire Now?
It may be oh-so tempting to cash out your upscale home and leave work for good. But should you? We ask the experts.
By Maurie Backman
-
Bouncing Back: New Tunes for Millennials Trying to Make It
Adele's mournful melodies kick off this generation's financial playlist, but with the right plan, Millennials can finish strong.
By Alvina Lo
-
Americans Are Retiring Later: Will This Trend Last?
Given a host of pressures to keep working, Americans are retiring later in life. Will regulatory and economic forces encourage you to work longer?
By Christy Bieber
-
Retiring Without a Partner? How Singles Can Maximize Their Savings
Retirement can be expensive, especially when you do it alone, surveys show. But there are ways to maximize your retirement savings even when facing your second act without a partner.
By Kathryn Pomroy
-
When Should You Hand Over the Keys — to Your Investments?
The secret to retirement planning? "The best time to hand over the keys is before you’ve realized you need to hand over the keys."
By Maurie Backman
-
Financial Steps After a Loved One's Alzheimer's Diagnosis
It's important to move fast on legal safeguards, estate planning and more while your loved one still has the capacity to make decisions.
By Thomas C. West, CLU®, ChFC®, AIF®
-
Two Don'ts and Four Dos During Trump's Trade War
The financial rules have changed now that tariffs have disrupted the markets and created economic uncertainty. What can you do? (And what shouldn't you do?)
By Maggie Kulyk, CRPC®, CSRIC™
-
I'm Single, With No Kids: Why Do I Need an Estate Plan?
Unless you have a plan in place, guess who might be making all the decisions about your prized possessions, or even your health care: a court.
By Cynthia Pruemm, Investment Adviser Representative